<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601366</url>
  </required_header>
  <id_info>
    <org_study_id>LNG-IUS-dysmenorrhea</org_study_id>
    <secondary_id>AUM001206</secondary_id>
    <nct_id>NCT01601366</nct_id>
  </id_info>
  <brief_title>LNG-IUS for Treatment of Dysmenorrhea</brief_title>
  <acronym>LNGIUSAD</acronym>
  <official_title>Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omar Mamdouh Shaaban</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenomyosis is a disease entity diagnosed when endometrial glands and stroma deep in the&#xD;
      myometrium are associated with surrounding myometrial hypertrophy. The finding classically&#xD;
      associated with adenomyosis is excessive uterine bleeding accompanied by worsening&#xD;
      dysmenorrhea. The advent of endovaginal US has substantially improved the ability to diagnose&#xD;
      adenomyosis. Different US features of adenomyosis have been reported, including uterine&#xD;
      enlargement not explainable by the presence of leiomyomas, asymmetric thickening of the&#xD;
      anterior or posterior myometrial wall, lack of contour abnormality or mass effect,&#xD;
      heterogeneous poorly circumscribed areas within the myometrium, anechoic lacunae or cysts of&#xD;
      varying sizes, and increased echotexture of the myometrium.&#xD;
&#xD;
      Transvaginal power Doppler application is useful in studying the vascular tree of adenomyosis&#xD;
      and can aid clinicians in planning the most appropriate therapeutic strategy. The&#xD;
      differential diagnosis using power Doppler sonography is based on vascular characteristics.&#xD;
      Adenomyosis is characterized by a preserved vascular texture supply that results in dilated&#xD;
      spiral arteries running perpendicular toward the myometrium into the endometrial surface.&#xD;
      Leiomyomata exhibits a vascular tree that typically circumscribes the solid mass. 2D&#xD;
      transvaginal power Doppler angiography should be used to improve diagnostic sensitivity and&#xD;
      facilitate appropriate therapeutic intervention.&#xD;
&#xD;
      The levonorgestrel-releasing intrauterine system (IUS), Mirena, has been approved in Europe&#xD;
      for contraception since 1990. Because of the suppressive effect of levonorgestrel on the&#xD;
      endometrium, Mirena has also been proven to be effective for the management of menorrhagia&#xD;
      and dysmenorrhea, and as a progestin component in postmenopausal hormone therapy. It was&#xD;
      introduced in Taiwan in 1995 as an alternative therapy for idiopathic menorrhagia. Many cases&#xD;
      of menorrhagia are caused by adenomyosis, and Mirena was, therefore, introduced for the&#xD;
      treatment of adenomyosis in Taiwan.&#xD;
&#xD;
      The current study is designed to evaluate the best treatment modality for treatment of&#xD;
      adenomyosis clinical by assessment of dysmenorrhea and or chronic pelvic pain by visual&#xD;
      analogue scale and menstrual blood loss by menstrual diary, imaging by ultrasound and Doppler&#xD;
      indices.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue score (VAS) for dysmenorrhea or chronic pelvic pain will be measure before after use LNG_IUS and COCs.</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Menstrual blood loss: assessment of blood loss, measured at the beginning of intervention and for 3 months</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>LNG-IUS (Mirena)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I &quot;the LNG-IUS group&quot; where they will have a LNG IUS (mirena) inserted for them</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined oral contraceptives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group II &quot;COCs group&quot; where they will receive low dose combined oral contraceptive pills for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LNG-IUS</intervention_name>
    <description>The study includes 2 treatment groups: Group I &quot;the LNG-IUS group&quot; where they will have a LNG IUS inserted for them</description>
    <arm_group_label>LNG-IUS (Mirena)</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined oral contraceptives</intervention_name>
    <description>Group II: will recite combined oral contraceptives for 6 months</description>
    <arm_group_label>Combined oral contraceptives</arm_group_label>
    <other_name>Gynera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women have dysmenorrhoea and/or chronic pelvic pain secondary to adenomyosis.&#xD;
&#xD;
          2. Planning for birth spacing for at least 2 years.&#xD;
&#xD;
          3. Patient aged between 20-45 years old.&#xD;
&#xD;
          4. Ultrasonographic and Doppler examination suggestive of adenomyosis.&#xD;
&#xD;
          5. Living in a nearby area to make follow-up reasonably possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Evidence of defective coagulation.&#xD;
&#xD;
          3. History or evidence of malignancy.&#xD;
&#xD;
          4. Hyperplasia in the endometrial biopsy.&#xD;
&#xD;
          5. Incidental adnexal abnormality on ultrasound.&#xD;
&#xD;
          6. Contraindications to COCs.&#xD;
&#xD;
          7. Absolute contraindication of LNG-IUS insertion.&#xD;
&#xD;
          8. Previous endometrial ablation or resection&#xD;
&#xD;
          9. Uninvestigated postcoital bleeding&#xD;
&#xD;
         10. Untreated abnormal cervical cytology&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Mamdouh Shaaban</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Adenomyosis</keyword>
  <keyword>Intrauterine levonorgestrel</keyword>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Oral contraceptives</keyword>
  <keyword>Uterus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

